Cargando…

Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival

Mesothelin is a cell surface associated antigen expressed on mesothelial cells and in some malignant neoplasms. Mesothelin-targeted therapies are in phase I/II clinical trials. The clinicopathologic and prognostic significance of mesothelin expression in triple negative breast carcinomas (TNBC) has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tozbikian, Gary, Brogi, Edi, Kadota, Kyuichi, Catalano, Jeffrey, Akram, Muzaffar, Patil, Sujata, Ho, Alice Y., Reis-Filho, Jorge S., Weigelt, Britta, Norton, Larry, Adusumilli, Prasad S., Wen, Hannah Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266616/ https://www.ncbi.nlm.nih.gov/pubmed/25506917 http://dx.doi.org/10.1371/journal.pone.0114900

Ejemplares similares

Genetic Alterations of Triple Negative Breast Cancer By Targeted Next Generation Sequencing And Correlation With Tumor Morphology
por: Weisman, Paul S, et al.
Publicado: (2016)

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
por: Eguchi, Takashi, et al.
Publicado: (2017)

Prognostic value of the immune microenvironment in lung adenocarcinoma
por: Kadota, Kyuichi, et al.
Publicado: (2013)

Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor
por: Piscuoglio, Salvatore, et al.
Publicado: (2016)

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
por: Kreike, Bas, et al.
Publicado: (2007)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Small RNA Sequencing for Profiling MicroRNAs in Long-Term Preserved Formalin-Fixed and Paraffin-Embedded Non-Small Cell Lung Cancer Tumor Specimens
por: Buitrago, Daniel H., et al.
Publicado: (2015)

A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
por: Del Bano, Joanie, et al.
Publicado: (2019)

Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
por: Wong, Willard, et al.
Publicado: (2021)

Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast
por: Geyer, Felipe C., et al.
Publicado: (2017)

Somatic mutations in leukocytes infiltrating primary breast cancers
por: Kleppe, Maria, et al.
Publicado: (2015)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy
por: Grabenstetter, Anne, et al.
Publicado: (2022)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
por: Ferraro, Emanuela, et al.
Publicado: (2022)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up
por: Turashvili, Gulisa, et al.
Publicado: (2018)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer
por: da Silva, Edaise M., et al.
Publicado: (2021)

Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
por: Pareja, Fresia, et al.
Publicado: (2016)

Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration
por: Kadota, Kyuichi, et al.
Publicado: (2015)

Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways
por: Pareja, Fresia, et al.
Publicado: (2017)

Near infrared photoimmunotherapy with an anti-mesothelin antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
por: Hilliard, Tyvette S.
Publicado: (2018)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
por: Faust, Joshua R., et al.
Publicado: (2022)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Do mesothelin/MUC16 interactions facilitate adenocarcinoma metastases to intracranial meningiomas?
por: Johnson, Mahlon D.
Publicado: (2016)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells
por: Lazzerini, Lea, et al.
Publicado: (2020)

Distant metastases
Publicado: (1998)

Association between mesothelin expression and survival outcomes in patients with triple-negative breast cancer: a protocol for a systematic review
por: Wang, Mei, et al.
Publicado: (2016)

Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin
por: Lurie, Eugene, et al.
Publicado: (2020)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hvr1cb70btjj38hi9sl7m57fu6